U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H5ClN2O
Molecular Weight 168.58
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOXAZOLAMINE

SMILES

NC1=NC2=C(O1)C=CC(Cl)=C2

InChI

InChIKey=YGCODSQDUUUKIV-UHFFFAOYSA-N
InChI=1S/C7H5ClN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)

HIDE SMILES / InChI

Molecular Formula C7H5ClN2O
Molecular Weight 168.58
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zoxazolamine is a centrally acting muscle relaxant. It decreased striatal dopamine metabolism without affecting striatal dopamine concentrations. More specifically, Zoxazolamine was shown to decrease striatal dopamine turnover without directly affecting dopamine synthesis, catabolism, reuptake, or release. It is the IK(Ca) channel opener. It was approved for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases. Later, it was submitted for the drug's use as a uricosuric agent to treat gout. It was withdrawn from the market due to hepatotoxicity.

Originator

Sources: DOI: 10.1021/ja01107a511

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Flexin

Approved Use

Zoxazolamine was indicated as a uricosuric agent to treat gout.

Launch Date

1956
Primary
Flexin

Approved Use

Zoxazolamine was indicated for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases

Launch Date

1956
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.5 mg/L
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOXAZOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
250 mg 4 times / day multiple, oral
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy, 40 years
Health Status: unhealthy
Age Group: 40 years
Sex: M
Sources:
Disc. AE: Hepatitis...
AEs leading to
discontinuation/dose reduction:
Hepatitis (acute, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hepatitis acute, 1 patient
Disc. AE
250 mg 4 times / day multiple, oral
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy, 40 years
Health Status: unhealthy
Age Group: 40 years
Sex: M
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Functional coupling of ATP-binding cassette transporter Abcb6 to cytochrome P450 expression and activity in liver.
2015-03-20
Halogen, hydrogen and electrostatic interactions in 2-amino-5-chloro-1,3-benzoxazol-3-ium nitrate and 2-amino-5-chloro-1,3-benzoxazol-3-ium perchlorate.
2010-09
Bioenhancers: Revolutionary concept to market.
2010-04
12-(4-Chloro-phen-yl)-9,9-dimethyl-9,10-dihydro-8H-benzo[a]xanthen-11(12H)-one.
2010-02-06
9,9-Dimethyl-12-(4-nitro-phen-yl)-9,10-dihydro-12H-benzo[a]xanthen-11(8H)-one.
2009-11-21
9,9-Dimethyl-12-phenyl-8,9-dihydro-12H-benzo[a]xanthen-11(10H)-one.
2009-11-07
Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes.
2009-08
Anti-clastogenic effect of magnolol-containing Hange-koboku-to, Dai-joki-to, Goshaku-san, and Magnoliae Cortex on benzo(a)pyrene-induced clastogenicity in mice.
2009-07
Inhibitory effect of magnolol on Trp-P-2-induced DNA damage in various organs in mice.
2009-07
Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR).
2009-02-04
Molecular and cellular basis of small--and intermediate-conductance, calcium-activated potassium channel function in the brain.
2008-10
Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function.
2008-09
Alterations in xenobiotic metabolism in the long-lived Little mice.
2007-08
The environmental estrogen, nonylphenol, activates the constitutive androstane receptor.
2007-08
Neutral genetic drift can alter promiscuous protein functions, potentially aiding functional evolution.
2007-06-28
Surgical correction of fixed kyphosis.
2007-06
Hepatoprotective potential of Aloe barbadensis Mill. against carbon tetrachloride induced hepatotoxicity.
2007-05-22
Transcription coactivator PRIP, the peroxisome proliferator-activated receptor (PPAR)-interacting protein, is redundant for the function of nuclear receptors PParalpha and CAR, the constitutive androstane receptor, in mouse liver.
2007
Gender-specific induction of cytochrome P450s in nonylphenol-treated FVB/NJ mice.
2006-10-15
Isolation, structure elucidation and in vivo hepatoprotective potential of trans-tetracos-15-enoic acid from Indigofera tinctoria Linn.
2006-10
Effect of some biologically interesting substituted tetrahydro-1,4-oxazines on drug metabolising enzymes and on inflammation.
2005-10
Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity.
2005-08-30
Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
2004-10-18
Functional and molecular identification of intermediate-conductance Ca(2+)-activated K(+) channels in breast cancer cells: association with cell cycle progression.
2004-07
Characteristics and a functional implication of Ca(2+)-activated K(+) current in mouse aortic endothelial cells.
2004-01
Inhibition of endothelium-dependent vasorelaxation by extracellular K(+): a novel controlling signal for vascular contractility.
2004-01
Effect of novel anti-inflammatory ethanolamine derivatives with antioxidant properties on drug metabolising enzymes.
2003-09-25
Effect of p-amino-diphenyl ethers on hepatic microsomal cytochrome P450.
2003-09
Unexpected down-regulation of the hIK1 Ca2+-activated K+ channel by its opener 1-ethyl-2-benzimidazolinone in HaCaT keratinocytes. Inverse effects on cell growth and proliferation.
2003-01-31
Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells.
2003-01-03
Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A.
2002-12
Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor.
2001-11
In vivo hepatoprotective activity of active fraction from ethanolic extract of Eclipta alba leaves.
2001-10
Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions.
2001-06
Hepatoprotective activity of indigtone--a bioactive fraction from Indigofera tinctoria Linn.
2001-06
Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds.
2001-03
Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene- and cigarette smoke condensate-induced cytogenetic damage in vivo.
2001-01
Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels.
2000-03
In-vivo effects of itraconazole on hepatic mixed-function oxidase.
1988-02
Effect of benzopyrone derivatives on drug activity and metabolism.
1986-10-01
The murine aromatic hydrocarbon responsiveness locus: a comparison of receptor levels and several inducible enzyme activities among recombinant inbred lines.
1986-03
Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides.
1974-11
Patents

Patents

Sample Use Guides

0.5 gm daily dose
Route of Administration: Oral
Mouse aortic endothelial cells were loaded with 0.5 uM Ca2+ in the pipette and current measured at 50 and −50 mV during repetitive ramps and the corresponding I/V curves constructed. 100 uM of zoxazolamine activated the K(Ca) current.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:45:04 GMT 2025
Edited
by admin
on Mon Mar 31 17:45:04 GMT 2025
Record UNII
9DOW362Q29
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZOXAZOLAMINE
INN   MI  
INN  
Official Name English
CONTRAZOLE
Preferred Name English
URI-BOI
Brand Name English
NSC-24995
Code English
FLEXIN
Brand Name English
ZOXAZOLAMINE [MI]
Common Name English
MIAZOL
Brand Name English
5-CHLORO-2-BENZOXAZOLAMINE
Systematic Name English
ZOXAMINE
Brand Name English
ZOXINE
Brand Name English
MCN-485
Code English
zoxazolamine [INN]
Common Name English
2-AMINO-5-CHLOROBENZOXAZOLE
Systematic Name English
DEFLEXOL
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C921
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
NCI_THESAURUS C29696
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
Code System Code Type Description
MESH
D015049
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
NSC
24995
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
EVMPD
SUB00192MIG
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
NCI_THESAURUS
C152966
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
PUBCHEM
6103
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
MERCK INDEX
m11669
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL472566
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
FDA UNII
9DOW362Q29
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
EPA CompTox
DTXSID1045245
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
INN
524
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
SMS_ID
100000078820
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
DRUG CENTRAL
2876
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
CAS
61-80-3
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
WIKIPEDIA
Zoxazolamine
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-519-4
Created by admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY